TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.

Sponsor: Novocure

https://clinicaltrials.gov/ct2/show/record/NCT06216301

Inclusion Criteria includes:

• ≥22 years of age in the USA.
• Stage 4 non-squamous or squamous NSCLC.
• Have not received prior systemic treatment for their metastatic NSCLC. Subjects who received chemotherapy or chemoradiotherapy for non-metastatic disease are eligible if the therapy was completed at least 12 months prior to the development of metastatic disease.

Exclusion Criteria include:

• Mixed small cell and NSCLC histology.
• Has received systemic therapy for metastatic disease.
• Received radiation therapy to the lung that is > 30 Gy within 6 months of randomization.
• Is expected to require any other form of antineoplastic therapy while on study.
• Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.